Austan Goolsbee Signals Potential for More Fed Rate Cuts as Inflation Shows Improvement 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
South Korea Warns Weak Won Could Push Inflation Higher in 2025 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Yen Near Lows as Markets Await Bank of Japan Rate Decision, Euro Slips After ECB Signals Caution 
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
New Zealand Business Confidence Hits 30-Year High as Economic Outlook Improves 
SK Bioscience recently inked a contract manufacturing organization (CMO) agreement with MSD which is also known as Merck & Co. The deal is for the production of the next-generation Zaire Ebola virus vaccine candidate.
The Vice Minister of the Ministry of Health and Welfare, Park Min Soo, MSD’s executive vice president Sanat Chattopadhyay, SK Bioscience’s chief executive officer Ahn Jae Yong, SK Disocvery’s vice chairman Chang Won Chey, Hillman Labs CEO, Raman Rao, and Representative of Global R&BD Kim Hoon were all present at the signing ceremony.
After the contract signing of the CMO deal with MSD, The Korea Herald reported that the stock price of SK Bioscience surged by 16.39% to KRW83,100 or about $64.04 late last week. The increase is said to be largely due to the hopes that the deal will improve the company’s slow sales performance.
In any case, SK Bioscience further confirmed the deal with MSD on Monday, May 8. It also provided more details about the CMO agreement today.
“For the growth and development of the biopharmaceutical industry, it is very important to promote cooperation between companies and establish its innovative ecosystem,” Park Min Soo said in a press release. “The Korean government is seeking various support measures, such as regulatory innovation and governance establishment, to promote cooperation between companies. We hope that this contract will continue a friendly cooperative relationship between MSD, Korea, and SK bioscience.”
MSD’s EVP and president of the manufacturing unit, Sanat Chattopadhyay, also said, “At MSD, we continue to seek innovative solutions to help expand access and help make our vaccines available when needed to people around the world. This agreement with SK bioscience, as part of our strong global manufacturing network, may enable us to further assist the global community in its response to future outbreaks of the Zaire Ebola virus.”
